Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : KI1106
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 29, 2018
Lead Product(s) : KI1106
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Melatonin on Sleep Disturbances in Patients With Parkinson's Disease
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 23, 2017
Lead Product(s) : Salsalate
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase IV
Recipient : Korea University Guro Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 19, 2017
Lead Product(s) : Salsalate
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase IV
Recipient : Korea University Guro Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : KI1107
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 20, 2017
Lead Product(s) : KI1107
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Melatonin
Therapeutic Area : Sleep
Study Phase : Phase II
Recipient : Seoul National University Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 03, 2016
Lead Product(s) : Melatonin
Therapeutic Area : Sleep
Highest Development Status : Phase II
Recipient : Seoul National University Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Melatonin on Sleep Disturbances in Patients With Parkinson's Disease
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 11, 2016
Lead Product(s) : Omega-3-Acid Ethyl Esters 90
Therapeutic Area : Endocrinology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 02, 2014
Lead Product(s) : Omega-3-Acid Ethyl Esters 90
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : KI1001
Therapeutic Area : Sleep
Study Phase : Phase III
Sponsor : Neurim Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of KI1001 in the Treatment of ≥ 55 Years Old Insomnia Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 14, 2014
Lead Product(s) : KI1001
Therapeutic Area : Sleep
Highest Development Status : Phase III
Sponsor : Neurim Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Atorvastatin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 14, 2014
Lead Product(s) : Atorvastatin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Irinotecan Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Daiichi Sankyo
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 18, 2013
Lead Product(s) : Irinotecan Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Daiichi Sankyo
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
